Charles de Rohan becomes CEO of The Binding Site
This article was originally published in Clinica
UK immunodiagnostics firm The Binding Site has appointed Charles de Rohan to the position of CEO. Mr de Rohan was previously the CEO of Genetix, a cell imaging and analysis firm that was acquired by Danaher in 2009. He has also worked for Abbott Laboratoires’ diagnostic division and began his career at Ernst & Young, where he trained as a chartered accountant. Birmingham-based The Binding Site is currently growing the international coverage of its leading product, the Freelite assay for diagnosis and monitoring of a cancer of cells in the bone marrow called multiple myeloma.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals